Telomere Testing and NAD+ Infusion Annua Diagram

Strengths

• Telomere testing provides quantifiable aging data, enhancing client trust.
• Annual subscription model locks in the long-term value of high-net-worth clients.
• NAD+ infusion treatments have high average transaction values with clear profit margins.

Weaknesses

• NAD+ infusion efficacy lacks large-scale clinical evidence, leading to skepticism.
• Telomere testing has low standardization, resulting in variations in result interpretation.
• High customer acquisition costs for high-net-worth segments and heavy reliance on word-of-mouth.

Opportunities

• Rising popularity of the longevity clinic sector reduces market education costs.
• Growing health anxiety and anti-aging demand among high-net-worth individuals.
• Potential for traffic-driving partnerships with insurance companies and high-end physical examination institutions.

Threats

• Regulatory policies tightening on the compliance of NAD+ infusions.
• Low-cost, gray-market NAD+ infusions disrupting market pricing.
• Entry of large medical institutions or pharmaceutical companies into the longevity clinic sector.